{"name":"Universität des Saarlandes","slug":"universit-t-des-saarlandes","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Alternative medications: carboplatin","genericName":"Alternative medications: carboplatin","slug":"alternative-medications-carboplatin","indication":"Ovarian cancer","status":"phase_3"},{"name":"Conventional Vincristine","genericName":"Conventional Vincristine","slug":"conventional-vincristine","indication":"Acute lymphoblastic leukemia (ALL)","status":"phase_3"},{"name":"R-miniCHOP","genericName":"R-miniCHOP","slug":"r-minichop","indication":"B-cell non-Hodgkin lymphoma in elderly or frail patients","status":"phase_3"},{"name":"R-miniCHOP + Acalabrutinib","genericName":"R-miniCHOP + Acalabrutinib","slug":"r-minichop-acalabrutinib","indication":"B-cell non-Hodgkin lymphoma (phase 3 investigation)","status":"phase_3"},{"name":"Ricover-scheme rituximab","genericName":"Ricover-scheme rituximab","slug":"ricover-scheme-rituximab","indication":"B-cell non-Hodgkin lymphoma (as part of R-CHOP/Ricover chemotherapy regimen)","status":"phase_3"},{"name":"optimised rituximab-schedule","genericName":"optimised rituximab-schedule","slug":"optimised-rituximab-schedule","indication":"Non-Hodgkin lymphoma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Vancomycine","genericName":"Vancomycine","slug":"vancomycine","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Alternative medications: carboplatin","genericName":"Alternative medications: carboplatin","slug":"alternative-medications-carboplatin","phase":"phase_3","mechanism":"Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill rapidly dividing cancer cells.","indications":["Ovarian cancer","Non-small cell lung cancer","Small cell lung cancer","Head and neck cancer","Breast cancer"],"catalyst":""},{"name":"Conventional Vincristine","genericName":"Conventional Vincristine","slug":"conventional-vincristine","phase":"phase_3","mechanism":"Vincristine is a vinca alkaloid that binds to tubulin and disrupts microtubule formation, causing cell cycle arrest in metaphase and triggering apoptosis in cancer cells.","indications":["Acute lymphoblastic leukemia (ALL)","Hodgkin lymphoma","Non-Hodgkin lymphoma","Rhabdomyosarcoma","Neuroblastoma"],"catalyst":""},{"name":"R-miniCHOP","genericName":"R-miniCHOP","slug":"r-minichop","phase":"phase_3","mechanism":"R-miniCHOP is a reduced-intensity chemotherapy regimen combining rituximab with a modified CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) backbone designed to treat lymphomas with lower toxicity.","indications":["B-cell non-Hodgkin lymphoma in elderly or frail patients"],"catalyst":""},{"name":"R-miniCHOP + Acalabrutinib","genericName":"R-miniCHOP + Acalabrutinib","slug":"r-minichop-acalabrutinib","phase":"phase_3","mechanism":"R-miniCHOP chemotherapy combined with acalabrutinib (a Bruton tyrosine kinase inhibitor) targets rapidly dividing lymphoma cells while blocking BTK signaling to enhance anti-tumor immunity.","indications":["B-cell non-Hodgkin lymphoma (phase 3 investigation)"],"catalyst":""},{"name":"Ricover-scheme rituximab","genericName":"Ricover-scheme rituximab","slug":"ricover-scheme-rituximab","phase":"phase_3","mechanism":"Rituximab is a monoclonal antibody that binds to CD20 on B cells, leading to their depletion and reduced antibody production in lymphoma and autoimmune conditions.","indications":["B-cell non-Hodgkin lymphoma (as part of R-CHOP/Ricover chemotherapy regimen)","Diffuse large B-cell lymphoma (DLBCL)"],"catalyst":""},{"name":"Vancomycine","genericName":"Vancomycine","slug":"vancomycine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"optimised rituximab-schedule","genericName":"optimised rituximab-schedule","slug":"optimised-rituximab-schedule","phase":"phase_3","mechanism":"Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.","indications":["Non-Hodgkin lymphoma","Rheumatoid arthritis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiS0FVX3lxTFBWbUp5WllHM3A3SHJ0RlZHUTI5OXc4N1RxUEhRcFlCMG8yM0Nral9BVEZ2NEdXNUVNY0dtdTFVeWtYQ0hvbVByUHZlOA?oc=5","date":"2026-03-12","type":"pipeline","source":"idw – Informationsdienst Wissenschaft","summary":"Optimised active substances against RSV - idw – Informationsdienst Wissenschaft","headline":"Optimised active substances against RSV - idw – Informationsdienst Wissenschaft","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNV2p1S29JcW1vZHM2aXNmNEwwdTBMaXhkTWFTa2pvYkp4R1daUkluQnNWM29fMHdHb0U3MFp6YlZjeEtkQ3hxWVVvbTFrRk9HRHc2TDl2VlctM2dpaU02NTlpTUw5ZEVvU2NqNkNHUldIUy0wWTdJMFRCWWVxODFjQlBBMzA1TUVIc0stME1seEV6bjhp?oc=5","date":"2026-01-31","type":"pipeline","source":"Legacy","summary":"Jurgen Venitz Obituary (2026) - Richmond, VA - Richmond Times-Dispatch - Legacy","headline":"Jurgen Venitz Obituary (2026) - Richmond, VA - Richmond Times-Dispatch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYWZZUU5TMm0xUkVOY2Q4Y05nNlI0NEtIdEZKVkNIWjQ0Q0NpSU5DY3pZQkFsUGxmbHdvY0Y0MWt6MEdUV3BrNW5vckVaUzFZdTJJRmNHcHQxanBwM1M5NUM4dG54eDJFMGtCNWVaNHlvTGVUNk41YzZvQXdpTUs4TEpXUGVtUHpmUXprb3RwS05tWXVzT3Roc0VSUU1BSUQwTjUyUGQ4VG9vY28?oc=5","date":"2024-08-11","type":"pipeline","source":"University of Alberta","summary":"Saarland University - University of Alberta","headline":"Saarland University","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTFA2Mlc3bV9vOXlkM1k3bk5qYVR2SElnMFFvOEV0QjhLUmtONHNITUVfam1nLXBRZ3VpLUtnVVM3dl9IQ3V3SXZfRTIxYnJ5aTY5VGpCZWlYa1dackk?oc=5","date":"2022-12-06","type":"pipeline","source":"idw – Informationsdienst Wissenschaft","summary":"EU funds Graduate School for drug research - idw – Informationsdienst Wissenschaft","headline":"EU funds Graduate School for drug research - idw – Informationsdienst Wissenschaft","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9QZVVidTBqOVRUVExLTW96YWJJY3VmR1hqemJLZUxoSWR3VURVTkNJQTlWQlFhNWgyOU5IU1BTZFJndzdwM0xjeDdFNm50ekdFRkItUFBpVkhUdnNNVjNEZHZ2dEFvclhrN2ZmcQ?oc=5","date":"2022-09-21","type":"trial","source":"Medical Xpress","summary":"Killer T cells get better with age, study finds - Medical Xpress","headline":"Killer T cells get better with age, study finds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBUb0lRREdFUDJGNDJEZ0wyZ3FGZk5MaG4wbDB2X2Z5ZnFTMUExdTVjUHBoMFdDRDZ5VFN5UGRwWFFabWFfSWwwVExJU21neTB1ckhz?oc=5","date":"2017-02-10","type":"pipeline","source":"nature.com","summary":"New natural products identified by combined genomics-metabolomics profiling of marine Streptomyces sp. MP131-18 - nature.com","headline":"New natural products identified by combined genomics-metabolomics profiling of marine Streptomyces sp. MP131-18","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9JZmVwc1M5bEJ1YlVaRjJ3LWlUZ0Z1Zl9XM3Q3RVdDc3RINGdzeXFoNmFtdEZUcTEzWVVkUjNmR2xoS3ZrTTBJN3RvdWtzWWhhNVRGdDhZRHlGM1E?oc=5","date":"2012-10-22","type":"pipeline","source":"Nanowerk","summary":"Lung mucus gel scaffold prevents nanoparticles from getting through - Nanowerk","headline":"Lung mucus gel scaffold prevents nanoparticles from getting through","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":6,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}